Siglec-10 (R119A), His & Avi, Human
| $390.00 | |
| Z05816-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $390.00 | |
| Z05816-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per ug by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 62.64 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 65-80 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in 20mM Tris,150mM NaCl, 200mM Arginine (pH 8.0). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized Siglec-10 (R119A), His & Avi, Human , His Tag at 1 μg/ml(100 μl/well) on the plate. Dose response curve for Anti-Siglec-10 Antibody, hFc Tag with the EC50 of 2.3ng/ml determined by ELISA. »
The purity of Siglec-10 (R119A), His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
Siglec-10 (R119A), His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Siglec-10 is a ligand for CD52, the target of the therapeutic monoclonal antibody Alemtuzumab. It is also reported to bind to Vascular adhesion protein 1 (VAP-1) and to the co-stimulatory molecule CD24 also known as HSA (Heat-stable antigen).Siglecs (sialic acid binding Ig-like lectins) are I-type lectins that belong to the immunoglobulin superfamily. They are characterized by an N-terminal Ig-like V-type domain which mediates sialic acid binding, followed by a varying number of Ig-like C2-type domains. Siglecs 5-11 constitute the CD33/Siglec-3 related group, and are differentially expressed in the hematopoietic system. |
| Synonyms | SLG2; SIGLEC10; MGC126774; PRO940 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.